Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.
Konstantin A KrychtiukGuillaume Marquis-GravelShannon MurphyKaren P AlexanderKaren ChiswellJennifer B GreenLawrence Alan LeiterRenato D LopesStefano Del PratoWilliam Schuyler JonesJohn J V McMurrayAdrian F HernandezChristopher B GrangerPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
Treatment with the GLP-1 receptor agonist albiglutide resulted in a 25% relative risk reduction in MI that was consistent for type of infarction and presence or absence of ST elevation. Our findings add novel information about the effects of GLP-1 receptor agonists on ischaemic events in patients with type 2 diabetes.